Regeneron is to collaborate with Inovio to investigate a three-way immunotherapy combination against glioblastoma multiforme (GBM), an aggressive and hard-to-treat brain tumour.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
